ABSTRACT
INTRODUCTION

Background
The Food and Drug Administration approved proton therapy utilization as early as 1988. 1 Over the last decade, there has been a rapid increase in the number of operating proton facilities in the United States, from 2 in 2003 to 22 in 2016. 2 While proton therapy utilization has continued to rise throughout the cancer community, there
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is an ongoing debate within the cancer community as to whether widespread clinical use is justified given the significant cost. There is a lack of comparative effectiveness data comparing proton to photon therapy and we may be jumping the gun on its use prior before comparative effectiveness data is mature. Radiation plays a critical role in the treatment of patients with head and neck cancer in the definitive, adjuvant, as well as recurrent salvage settings. Due to the anatomy of the head and neck and the close proximity of the tumor target to normal critical structures at risk, such as optic nerves, orbits, salivary glands, brain, pituitary grand, carotid arteries, reducing radiation toxicity is paramount. The dose distribution with proton therapy limits dose deposition after a finite distance from the Bragg peak and more normal tissue sparing is expected. Therefore, there has been an increased interest in harnessing the unique physical properties of proton therapy in order to dose escalate radiation delivered to the tumor while decreasing dose to normal tissue with the aim of decreasing treatment toxicity. In addition, just as with photon therapy, the development of intensitymodulated proton therapy (IMPT) has enabled enhanced dosimetric optimization. 3 There are many studies in the development that are assessing the benefit of protons in head and neck cancer. In a study by van der Laan et al, 4 IMPT was superior to intensity-modulated radiation therapy (IMRT) in terms of decreased dose to pharyngeal constrictors, thereby estimating an 8% decrease in grade II to IV dysphagia. Others have proposed that a reduction in dose to the posterior fossa achievable with IMPT may result in decreased treatment-related fatigue. 5 However, these dosimetric-based studies have not yet been analyzed to assess whether they do in fact translate to the proposed clinical benefit. A larger dosimetric advantage with proton therapy use is appreciable in the setting of ipsilateral treatment targets, such as salivary tumors or early tonsillar tumors. 6 In a study by Romesser et al, 7 41 patients who underwent ipsilateral RT for major salivary gland cancer or cutaneous squamous cell carcinoma were examined, 56% treated with IMRT and 44% with proton beam RT (PBRT The two groups, however, were not well balanced as higher risk histologies were in the photon group and the dose delivered was equivalent. These results are encouraging and emphasize the need for more randomized trials in various head and neck subsites. In spite of significant advances in initial treatment of head and neck cancers, locoregional recurrences will develop in a significant percentage of patients, which may be managed by surgery or reirradiation. In the largest multi-institutional series on proton reirradiation therapy, 92 patients with recurrent head and neck cancer previously treated with radiation were examined. 15 The cumulative index of 1 year locoregional failure was 25.1%, while OS was 65.2%. Acute grade ≥3 toxicity rates were very low and included mucositis (9.9%), dysphagia (9.1%), esophagitis (9.1%), and dermatitis (3.3%). Late grade ≥3 toxicity rates were also low, with dermatitis occurring in 8.7% and dysphagia in 7.1%. These reported toxicities favorably compare with photon reirradiation in which dermatitis is in the range of 13 to 32% and mucositis 13 to 43%. 16, 17 Unfortunately, two patients without evidence of disease developed grade V bleeding, likely due to blood vessel injury. In this study, locoregional control and survival outcomes were substantial, while toxicity was limited as compared with historical studies using photon therapy. The authors emphasize that additional prospective studies are warranted and they plan to prospectively validate the study and include cost-effectiveness data. Notwithstanding all possible therapeutic gains associated with proton therapy dose distribution, its use in head and neck has been challenged by heterogeneity of volume density, especially sinuses (air gaps, bone) and tumor volume changes and anatomic shifts over the course of treatment. Changes in density and volumes of the course of treatment may adversely impact dose delivery. 18 The value of proton therapy has been studied in many cancers, such as lung and prostate. In a recent randomized phase III study examining proton (3D) vs photons in locally advanced non-small cell lung cancer, there was no added benefit to proton therapy, and treatment failure rates at 1 year were higher with proton therapy 24.6 vs 15.6%. 19 While these results are still in abstract form, the outcomes warrant further investigation as primary endpoint of radiation pneumonitis was not met and in fact radiation pneumonitis was numerically worse, with proton therapy 11% vs IMRT 7.2%. Moreover, there was a trend for worse survival with proton therapy 26.1 vs 29.5 months with photon therapy. In another study on prostate cancer, at 1 year posttreatment, there was no difference in genitourinary toxicity (18.8 vs 17.5%; OR =1.08, 95% CI= 0.76-1.54, p = 0.66). Moreover, there was no statistically significant difference in gastrointestinal toxicity at 6 or 12 months posttreatment. 20 The lack of clear benefit thus far does not justify the higher cost associated with protons in this patient context. Table 1 . A direct comparison of treatment modalities, proton vs photon radiation therapy in head and neck cancer, is NCT01893307. This is a phase II/III randomized trial of IMPT vs IMRT for the treatment of oropharyngeal cancer of the head and neck. The primary outcome of the study assesses the rate and severity of late grade III to V toxicity between IMRT and IMPT with an expected accrual of 360 patients and completion date of 2023.
Indeed, additional randomized studies are required to ascertain the comparative effectiveness of different ijhns radiation types. Moreover, compounding these challenges, the definitions of comparative effectiveness, incremental effectiveness, and cost vary among stakeholders and countries. 23 Medicare reimbursements for proton beam therapy is estimated two to three times that of IMRT. One proposed suggestion to curb costs until evidence accrues is suggested by Bekelman and Hahn, 24 wherein payers will reimburse proton therapy at the photon therapy rate provided patients participate in trials that are expected to generate high-quality evidence. This reference pricing model maintains access to proton therapy with the aim of expanding the necessary research needed. The Centers for Medicare and Medicaid Services does not use cost-effectiveness data to make coverage decisions, which contrasts the views of the UK National Institute for Health and Care Excellence, which considers cost per quality-adjusted life-year when making coverage recommendations. 23 The American Society for Radiation Oncology has addressed proton coverage for head and neck cancer as suitable for coverage with evidence development, if the patient is enrolled in an institutional review board-approved clinical trial or multi-institutional patient registry.
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CONCLUSION
There are many potential advantages to radiation therapy with protons. While there are many single institution studies examining the added value of protons to photon therapy, the value of proton therapy must be examined in prospective randomized clinical studies and across many subsites of head and neck cancer. Additional evidence is necessary to guide efficient clinical practice, patient selection, and tumors that are most likely to benefit from this treatment modality and justify proton therapy use given its significant cost. 
